FMBA and Rosatom have created a roadmap for the development of radiopharmaceuticals


The FMBA of Russia and Rosatom State Corporation have jointly developed a roadmap for the development of nuclear medicine and other medical technologies. The document provides for joint research and development of appropriate infrastructure, including the creation of pilot production, the press service of the FMBA said.

Until 2027, FMBA and Rosatom will conduct preclinical and clinical studies of innovative radiopharmaceuticals, with their further potential registration and market launch. In addition, according to the report, “it is planned to create, develop and improve the system of continuing professional education for research, engineering and medical personnel in the field of production of radiopharmaceuticals and specialized medical devices.”

Earlier, the FMBA received a grant in the amount of 92 m rubles for the development of cell-based therapies and medicines based on tissue engineering technologies. Lomonosov Moscow State University and the Ministry of Education and Science of the Russian Federation have also received funds for the same purposes, in the amount of 503 million rubles.